Table 2.
Summary of efficacy of anti-HMGB1 m2G7 in HMGB1-driven inflammatory diseases.
| Models/species | Findings | References |
|---|---|---|
| Infectious diseases | ||
| CLP sepsis or endotoxemia in mice | Reduced lethalit y in CLP-induced sepsis and in endotoxemia | (11, 34) |
| CLP sepsis-survivors in mice | Reduced sepsis-induced memory impairments and brain pathology in survivors | (49) |
| CLP sepsis-survivors in mice | Ameliorated sepsis-induced development of anemia and stress erythropoiesis | (49, 50) |
| Sterile injury | ||
| Islet transplantation in diabetic mice | Improved islet viability and reduced transplantation-induced inflammation | (51) |
| Chronic arthritis in mice | Ameliorated clinical arthritis scores, partially prevented joint destruction | (52) |
| Arthritis pain in mice | Ameliorated pain-like behavior in collagen antibody induced arthritis | (53) |
| Acetaminophen (APAP)-induced liver toxicity in mice | Attenuated APAP-induced release of ALT, microRNA-122, and abrogated inflammation | (9, 54) |
| Autoimmune myocarditis in mice | Reduced cardiac inflammation | (55) |
| Puhnonary hypertension in rats | Improved survival in monocrotaline-induced severe puhnonary hypertension | (47) |